Pfizer and Valneva have shared promising immune response and safety results from a mid-stage study of their Lyme disease ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed ...

The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of their dedication to and ...

Roche has announced positive new 48-week data for investigational fenebrutinib in patients with relapsing forms of multiple ...

Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative ...

Moderna’s JN.1-adapted COVID-19 vaccine has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in adults and children aged six months and older. The adaption ...

Delivering on your brand or portfolio strategy can come with some sizeable questions that need to be tackled in order to progress. And not just progress but place you in the best position to achieve ...

Eli Lilly and HAYA Therapeutics have entered into a multi-year agreement worth up $1bn to discover regulatory genome targets for obesity and related metabolic conditions. The collaboration centres ...

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants The announcement comes just over a week after the regulator approved updated ...

Worldwide Clinical Trials (Worldwide), a global full-service contract research organisation, has appointed Alessandra Vignola as president of the cardiovascular and metabolic business unit. Vignola ...

Biogen has shared positive top-line results from a phase 2/3 study evaluating a higher dose regimen of its antisense oligonucleotide nusinersen in spinal muscular atrophy (SMA). The drug is already ...